Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    July 2018
  1. WEBSTER P
    Hepatitis C treatment in Guatemala: the struggle for access.
    Lancet. 2018;392:269-270.
    PubMed     Text format    


  2. THE LANCET
    Transforming treatment for hepatitis C.
    Lancet. 2018;392:254.
    PubMed     Text format    


    June 2018
  3. WEBSTER P
    Hepatitis C-infected organ transplants offer hope.
    Lancet. 2018;391:2485.
    PubMed     Text format    


    April 2018
  4. CHEN S, Li J, Wang D, Fung H, et al
    The hepatitis B epidemic in China should receive more attention.
    Lancet. 2018;391:1572.
    PubMed     Text format    


    March 2018
  5. WANDELER G, Coffie PA, Kuniholm MH, Ocama P, et al
    Issues with measuring hepatitis prevalence in resource-limited settings.
    Lancet. 2018;391:835-836.
    PubMed     Text format    


  6. MOIN A, Fatima H, Qadir TF
    Tackling hepatitis C-Pakistan's road to success.
    Lancet. 2018;391:834-835.
    PubMed     Text format    


    November 2017
  7. WILLIAMS R, Alexander G, Armstrong I, Baker A, et al
    Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.
    Lancet. 2017 Nov 28. pii: S0140-6736(17)32866.
    PubMed     Text format     Abstract available


  8. THE LANCET
    Eliminating viral hepatitis: time to match visions with action.
    Lancet. 2017;390:2121.
    PubMed     Text format    


  9. GARTNER C, Miller A, Bonevski B
    Extending survival for people with hepatitis C using tobacco dependence treatment.
    Lancet. 2017;390:2033.
    PubMed     Text format    


    September 2017
  10. GARCIA-TARDON N, Gresnigt TM, Fofanah AB, Grobusch MP, et al
    Hepatitis B and C in Tonkolili Province, Sierra Leone.
    Lancet. 2017;390:1485.
    PubMed     Text format    


    July 2017
  11. GREEN A
    The omitted epidemic-hepatitis E in the Lake Chad region.
    Lancet. 2017;390:443-444.
    PubMed     Text format    


  12. THE LANCET
    Growing concerns of hepatitis E in Europe.
    Lancet. 2017;390:334.
    PubMed     Text format    


  13. WIKTOR SZ, Scott JD
    What is the impact of treatment for hepatitis C virus infection?
    Lancet. 2017;390:107-109.
    PubMed     Text format    


  14. DOYLE JS, Thompson AJ, Higgs P, Stoove M, et al
    New hepatitis C antiviral treatments eliminate the virus.
    Lancet. 2017 Jul 6. pii: S0140-6736(17)31817.
    PubMed     Text format    


    February 2017
  15. EKSER B, Mangus RS
    Spontaneous bacterial peritonitis.
    Lancet. 2017;389:735.
    PubMed     Text format    


    January 2017
  16. VAN DER REE MH, de Vree JM, Stelma F, Willemse S, et al
    Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
    Lancet. 2017 Jan 10. pii: S0140-6736(16)31715.
    PubMed     Text format     Abstract available


  17. ZEISEL MB, Baumert TF
    Clinical development of hepatitis C virus host-targeting agents.
    Lancet. 2017 Jan 10. pii: S0140-6736(17)30043.
    PubMed     Text format    


    December 2016
  18. LIVINEC B
    Estimating the burden of hepatitis.
    Lancet. 2016;388:2738-2739.
    PubMed     Text format    


    November 2016
  19. GHINEA N, Lipworth W, Day R, Hill A, et al
    Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
    Lancet. 2016 Nov 3. pii: S0140-6736(16)32051.
    PubMed     Text format    


    October 2016
  20. GAO YQ, Zhang X, Li M, Zhou ZH, et al
    Bushenjianpi formula combined with entecavir for HBeAg-negative chronic hepatitis B patients: a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2016;388 Suppl 1:S33.
    PubMed     Text format     Abstract available


    September 2016
  21. MOHAMMADI D
    Lasker Foundation announces award winners for 2016.
    Lancet. 2016;388:1144-5.
    PubMed     Text format    


  22. PIROTH L, Rabaud C, Rey D, Schmit JL, et al
    Hepatitis C: the path towards effective universal therapy.
    Lancet. 2016;388:1051-2.
    PubMed     Text format    


    July 2016

  23. Towards elimination of viral hepatitis by 2030.
    Lancet. 2016;388:308.
    PubMed     Text format    


  24. KAMARULZAMAN A, Reid SE, Schwitters A, Wiessing L, et al
    Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30769.
    PubMed     Text format     Abstract available


  25. ALTICE FL, Azbel L, Stone J, Brooks-Pollock E, et al
    The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30856.
    PubMed     Text format     Abstract available


  26. DOLAN K, Wirtz AL, Moazen B, Ndeffo-Mbah M, et al
    Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30466.
    PubMed     Text format     Abstract available


  27. RICH JD, Beckwith CG, Macmadu A, Marshall BD, et al
    Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30379.
    PubMed     Text format     Abstract available


  28. RUBENSTEIN LS, Amon JJ, McLemore M, Eba P, et al
    HIV, prisoners, and human rights.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30663.
    PubMed     Text format     Abstract available


  29. RATHI S
    Rules and rues.
    Lancet. 2016;388:122-3.
    PubMed     Text format    


  30. STANAWAY JD, Flaxman AD, Naghavi M, Fitzmaurice C, et al
    The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.
    Lancet. 2016 Jul 6. pii: S0140-6736(16)30579.
    PubMed     Text format     Abstract available


  31. WIKTOR SZ, Hutin YJ
    The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts.
    Lancet. 2016 Jul 6. pii: S0140-6736(16)31018.
    PubMed     Text format    


    May 2016
  32. 'T HOEN EF
    Indian hepatitis C drug patent decision shakes public health community.
    Lancet. 2016 May 26. pii: S0140-6736(16)30656.
    PubMed     Text format    



  33. Hepatitis C: global ambition, national realities.
    Lancet. 2016;387:1970.
    PubMed     Text format    


  34. KELLY D
    Hepatitis C viraemia after apparent spontaneous clearance.
    Lancet. 2016;387:1968.
    PubMed     Text format    


  35. INDOLFI G, Mangone G, Bartolini E, Moriondo M, et al
    Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child.
    Lancet. 2016;387:1967-8.
    PubMed     Text format    


    April 2016
  36. LOCARNINI S, Chen DS, Shibuya K
    No more excuses: viral hepatitis can be eliminated.
    Lancet. 2016;387:1703-4.
    PubMed     Text format    


    March 2016
  37. CSETE J, Kamarulzaman A, Kazatchkine M, Altice F, et al
    Public health and international drug policy.
    Lancet. 2016 Mar 23. pii: S0140-6736(16)00619.
    PubMed     Text format    


  38. CORRIGAN M, Alrubaiy L, China L
    Hepatology training in the UK.
    Lancet. 2016;387:1055.
    PubMed     Text format    


    January 2016
  39. MCCALL C
    Australia commits funds to curb hepatitis C epidemic.
    Lancet. 2016;387:419.
    PubMed     Text format    


    November 2015
  40. WILLIAMS R, Ashton K, Aspinall R, Bellis MA, et al
    Implementation of the Lancet Standing Commission on Liver Disease in the UK.
    Lancet. 2015;386:2098-111.
    PubMed     Text format    



  41. Hepatitis C: cost of lost opportunities.
    Lancet. 2015;386:1917.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: